Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas

Journal of the American Academy of Dermatology

Volumn 47, Issue 4, 2002, Pages 623-628

  Shapiro, Michael ^a   Yun, Mijin ^a   Junkins Hopkins, Jacqueline M ^a   Vittorio, Carmela C ^a   Schulman, Norman ^b   Saidman, Bruce H ^c   Fried, Richard G ^d   Rook, Alain H ^a   Alavi, Abass ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Radiation Medicine Specialists of NEPA   (United States)

^c Medical Oncology Associates   (United States)

^d Yardley Dermatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; FLUORODEOXYGLUCOSE F 18;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; FEMALE; FEVER; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHADENOPATHY; LYMPHOMA; MALE; PANNICULITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SKIN LYMPHOMA; T CELL LYMPHOMA; TUMOR RECURRENCE;

EID: 0036789596     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.124076     Document Type: Article

References (53)

1. Karp JS, Muehllehner G, Qu H, Yan XH. Signal transmission in volume-imaging PET with a 137Cs source. Phys Med Biol 1995;40:929.
2. Bedigian MP, Benard F, Smith RJ, Karp JS, Alavi A. Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. Eur J Nucl Med 1998;25:659.
3. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-50.
4. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
5. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
6. Salhany KE, Macon WR, Choi JK, Elenitsas R, Lessin SR, Felgar RE, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998;22:881-93.
7. Perniciaro C, Zalla MJ, White JW, Menke DM. Subcutaneous T-cell lymphoma: report of two additional cases and further observations. Arch Dermatol 1993;129:1171-6.
8. Wang CYE, Su WPD, Kurtin PJ. Subcutaneous panniculitic T-cell lymphoma. Int J Dermatol 1996;35:1-8.
9. Gonzalez CL, Medeiros U, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991;15:17-27.
10. Chin-Yao EW, Daniel Su WP, Kurutin PJ. Subcutaneous panniculitic T-cell lymphoma. Int J Dermatol 1996;35:1-8.
11. Jaffe ES, Costa J, Fauci AS, Cossman J. Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med 1983;75:541-9.
12. Smith KJ, Skelton HG, Yeager J, Angritt P, Wagner K, James WD, et al. Cutaneous histopathologic, immunohistochemical, and clinical manifestations in patients with hemophagocytic syndrome. Arch Dermatol 1992;128:193-200.
13. Kumar S, Krenacs L, Medeiros J, Elenitoba-Johnson KS, Greiner TC, Sorbara L, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998;29:397-403.
14. Felgar RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE. TIA-1 expression in lymphoid neoplasms: identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 1997;150:1893-900.
15. Hashimoto H, Sawada K, Koizumi K, Nishio M, Endo T, Takashima T, et al. Effective CD34+ selected autologous peripheral blood stem cell transplantation in a patient with subcutaneous panniculitic T cell lymphoma (SPTCL) transformed into leukemia. Bone Marrow Transplant 1999;24:1369-71.
16. Koizumi K, Sawada K, Nishio M, Katagiri E, Fukae J, Fukada Y, et al. Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Bone Marrow Transplant 1997;20:171-3.
17. Haycox CL, Back AL, Raugi GJ, Piepkorn M. Subcutaneous T-cell lymphoma treated with systemic chemotherapy, autologous stem cell support, and limb amputation. J Am Acad Dermatol 1997;37: 832-5.
18. 389IL-2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol 1998;58:87-90.
19. 389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39:63-73.
20. Au WY, Ng WM, Choy C, Kwong YL. Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone, and dexamethasone. Br J Dermatol 2000;143: 408-10.
21. Willemze R. New concepts in the classification of cutaneous lymphomas. Arch Dermatol 1995;131:1077-80.
22. Gilliam AC, Wood GS. Primary cutaneous lymphomas other than mycosis fungoides. Semin Oncol 1999;26:290-306.
23. Pimpinelli N, Santucci M, Carli P, Paglierani M, Bosi A, Moretti S, et al. Primary cutaneous follicular center cell lymphoma: clinical and histological aspects. In: van Vloten WA, Willemze R, Lange Vejlsgaard G, Thomsen K, editors. Cutaneous lymphoma. Basel: Karger; 1990. p. 203-20.
24. Clayton AS, McCollough M, Barekman CL. Primary cutaneous B-cell lymphoma. Cutis 1998;62:69-72.
25. Pimpinelli N, Santucci M, Bosi A, Moretti S, Vallecchi C, Messori A, et al. Primary cutaneous follicular center-cell lymphoma: a lymphoproliferative disease with favourable prognosis. Clin Exp Dermatol 1989;14:12-9.
26. Willemze R, Meijer CJLM, Sentis HJ, Scheffer E, van Vloten WA, Toonstra J, et al. Primary cutaneous large cell lymphomas of follicular center cell origin. J Am Acad Dermatol 1987;16:518-26.
27. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases. Cancer 1991;67:2311-26.
28. Bekkenk MW, Vermeer MH, Geerts ML, Noordijk EM, Heule F, van Voorst Vader PC, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 1999;17:2471-8.
29. Piccinno R, Caccialanza M, Berti E, Baldini L. Radiotherapy of cutaneous B cell lymphomas: our experience in 31 cases. Int J Radiat Oncol Biol Phys 1993;27:385-9.
30. Rijlaarsdam JU, Toonstra J, Meijer OW, Noordijk EM, Willemze R. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 1996;14:549-55.
31. Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000; 136:374-8.
32. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder PJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
33. Kempf W, Dummer R, Schmid MH, Fritz T, Wuthrich B, Burg G. Intralesional cisplatin for the treatment of cutaneous B-cell lymphoma. Arch Dermatol 1998;134:1343-5.
34. Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferi associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991;24: 584-90.
35. Cerroni L,Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997;24:457-61.
36. Kicuchi A. Treatment of B cell lymphoma of the skin. Australas J Dermatol 1996;37:S34-5.
37. Nagatani T, Miyazawa M, Matsuzaki T, Hayakawa H, Iemoto G, Kim ST, et al. Cutaneous B-cell lymphoma-a clinical, pathological, and immunohistochemical study. Clin Exp Dermatol 1993;18:530-6.
38. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In: Warburg O, editor. Metabolism of tumors. London: Constable; 1930. p. 254-70.
39. Shreve PD, Anzai Y, Wahl R. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61.
40. Cook G, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363.
41. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 1996;10:185.
42. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole-body 2-deoxy-2-[F18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
43. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-81.
44. Martinez-Lazaro R, Cortes-Blanco A, Zhuang HM, Alavi A. Whole-body FDG-PET imaging for assessment of tumor grade of non-Hodgkin's lymphoma and Hodgkin's disease [abstract]. J Nucl Med 2000;40(Suppl):279.
45. Benard F, Sterman D, Smith PJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-5.
46. Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral gliomas using positron emission tomography with 18F-fluorodeoxyglucose. J Neurol Oncol 1991;10:85-91.
47. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83:918-24.
48. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994;8:187-91.
49. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-90.
50. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12-7.
51. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861-6.
52. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
53. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.